Intact Therapeutics GTM brain

category

market profile

• text: The company describes itself as clinical stage; its disclosed programs include a thermogel for upper GI bleeding and INT-102 for distal ulcerative colitis, with current program status requiring confirmation.
• text: A 2025 option agreement for a gastroparesis drug candidate indicates potential interest beyond its original gel platform, but exercise and subsequent status are unconfirmed.

personas

• title: Gastroenterologist treating distal ulcerative colitis
  pains:

  • Patients may struggle to retain liquid enemas and need sustained, localized treatment.
  • Systemic therapies can carry adverse effects and fail to achieve response.
• title: Hospital emergency medicine or GI clinical leader
  pains:

  • Upper GI bleeding requires rapid stabilization before endoscopy can be performed.
  • A new product would need safety and clinical outcome evidence before adoption.
• title: GI pharmaceutical business development leader
  pains:

  • Building a differentiated GI pipeline requires evidence on candidate fit, clinical development and licensing economics.
  • A drug delivery platform must prove compatibility and manufacturability for the specific asset.

icp

• text: Potential clinical users include hospitals and gastroenterology practices treating upper GI bleeding or distal ulcerative colitis; commercial availability is not established.
• text: Potential development partners include biotech and pharmaceutical companies with GI drug programs or licensing interests; partner fit is inferred, not a published account-size requirement.

message pillars

• text: Develop next-generation treatments for gastrointestinal disease.
• text: Concentrate on unmet clinical needs.
• text: Put outcomes and patient quality of life at the center.

objections

• objection: Is this approved and clinically proven for the intended use?
  response: Request current trial data and indication-specific regulatory status; the cited research programs are investigational.
• objection: How does a gel compare with standard topical therapy?
  response: Ask for full comparative retention, patient acceptability and efficacy data; the goal is better local delivery, not a guarantee of superior outcomes.
• objection: Will this work with our drug or development strategy?
  response: Assess molecule compatibility, manufacturing and terms with the company; these are not established publicly.

competitors

• name: Alivio Therapeutics
  why: Developed an inflammation-targeted hydrogel approach to local drug delivery for inflammatory disease.
• name: Biora Therapeutics
  why: Developed an ingestible device to deliver medication directly to the colon, an alternative delivery approach.

keywords

• gastrointestinal drug delivery
• ulcerative colitis topical therapy
• thermogel drug delivery
• upper GI bleeding treatment
• colon targeted drug delivery
• gastrointestinal drug licensing

voice

• clinical
• patient centered
• mission led

signals

• text: A GI drug developer is assessing delivery approaches for distal ulcerative colitis or other gut-localized treatments.
• text: A hospital research group is investigating stabilization of upper GI bleeding before endoscopy.

pricing

motion

confidence

Founders

• name: Ravi Pamnani
  title: Founder/CEO
  role: CEO
  bio: Passionate about intersection of health and technology.
• name: Sidhartha Sinha
  title: Founder
  role: Founder